ENGLEWOOD, Colo., Jan. 2, 2018 /PRNewswire/ -- Aytu BioScience,
Inc. (NASDAQ: AYTU), a specialty life sciences company focused on
global commercialization of novel products in the field of urology,
today announced that Josh Disbrow,
Chairman & Chief Executive Officer, and Jarrett Disbrow, Chief Operating Officer, will
present a corporate overview at the Biotech Showcase 2018 Investor
Conference taking place on January 8-10,
2018 at the Hilton San Francisco Union Square, San Francisco, CA.
Aytu's management will present on Tuesday, January 9th at 9:30 AM PT in Yosemite-C (Ballroom level) and
will be meeting with investors throughout the conference. The
investor presentation will be available at
http://aytubio.com/investors/corporate-presentations-media/.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences
company focused on global commercialization of novel products in
the field of urology, with a focus on products addressing vitality,
sexual wellness, and reproductive health. The Company currently
markets two prescription products in the U.S.: Natesto®, the first
and only FDA-approved nasal formulation of testosterone for men
with hypogonadism (low testosterone, or "Low T") and ProstaScint®
(capromab pendetide), the only FDA-approved imaging agent specific
to prostate specific membrane antigen (PSMA) for prostate cancer
detection and staging. Additionally, Aytu is developing MiOXSYS®, a
novel, rapid semen analysis system with the potential to become a
standard of care for the diagnosis and management of male
infertility caused by oxidative stress. MiOXSYS® is commercialized
outside the U.S. where it is a CE Marked, Health Canada cleared,
and TGA approved product, and Aytu is planning U.S.-based clinical
trials in pursuit of 510k medical
device clearance by the FDA. Aytu's strategy is to continue
building its portfolio of revenue-generating products, leveraging
its focused commercial team and expertise to build leading brands
within growing markets. For more information visit aytubio.com.
Aytu also now owns wholly-owned subsidiary Aytu Women's Health
(formerly Nuelle, Inc.), a personal health and wellness company
focused on women's sexual wellbeing and intimacy. Aytu Women's
Health markets Fiera, a personal care device for women that is
scientifically proven to enhance physical arousal and sexual
desire. Fiera is a consumer device and is not intended to treat,
mitigate, or cure any disease or medical condition. For more
information about the Fiera personal care device visit
fiera.com.
Forward Looking Statement
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of
historical facts contained in this presentation, including
statements regarding our anticipated future clinical and regulatory
events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking
statements. Forward looking statements are generally written in the
future tense and/or are preceded by words such as "may," "will,"
"should," "forecast," "could," "expect," "suggest," "believe,"
"estimate," "continue," "anticipate," "intend," "plan," or similar
words, or the negatives of such terms or other variations on such
terms or comparable terminology. These statements are just
predictions and are subject to risks and uncertainties that could
cause the actual events or results to differ materially. These
risks and uncertainties include, among others: risks relating to
gaining market acceptance of our products, the potential
future commercialization of our product candidates, the anticipated
start dates, durations and completion dates, as well as the
potential future results, of our ongoing and future clinical
trials, the anticipated designs of our future clinical trials,
anticipated future regulatory submissions and events, and future
events under our current and potential future collaborations. We
also refer you to the risks described in "Risk Factors" in Part I,
Item 1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and
in the other reports and documents we file with the Securities and
Exchange Commission from time to time.
Investor contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aytu-bioscience-to-present-at-biotech-showcase-2018-investor-conference-300576198.html
SOURCE Aytu BioScience, Inc.